Literature DB >> 16855377

The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis.

J Nyagol1, E Leucci, A Onnis, G De Falco, C Tigli, F Sanseverino, M Torriccelli, N Palummo, L Pacenti, R Santopietro, D Spina, P Gichangi, L Muchiri, S Lazzi, F Petraglia, L Leoncini, A Giordano.   

Abstract

The role of HPV in the carcinogenesis of intraepithelial and invasive anogenital lesions is currently well established. E6 and E7 oncoproteins of high-risk HPV genotypes are known to inactivate p53 and pRb pathways. Several studies have described an increased prevalence and recurrence of both cervical HPV infection and invasive cervical cancer among HIV-1 positive women compared to HIV-1 negative cases. For these reasons, cervical cancer is considered an AIDS-defining neoplasm. Unlike other AIDS-associated neoplasms, the occurrence of cervical cancer is independent of immune suppression. HIV-1 infection in patients with high grade precancerous lesions and invasive cervical cancers results in a therapy refractory and more aggressive disease phenotype, which is not yet well understood at the molecular level. An upregulation of HPV E6 and E7 gene expressions by HIV-1 proteins such as Tat has been documented by some authors. However, the role of HIV-1 in cervical carcinomas is still unclear. It is already known that HIV-1 Tat protein is able to influence cell cycle progression. Altogether, these facts led us to investigate the effects of Tat on the expression of cell cycle regulator genes. After transfection of HeLa cells with Tat, we analyzed the expression of cell cycle regulators from these cells by IHC and Real-time PCR. A significant reduction in the expression of cell cycle inhibitors of transcription and an increase in the levels of proliferation markers were observed. These results suggest that HIV-1 may enhance cervical carcinogenesis by promoting cell cycle progression. We also found that this HIV-1 Tat-induced cell proliferation was not dependent on the E2F family of transcription factors, and therefore postulate that Sp factors may be involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855377     DOI: 10.4161/cbt.5.6.2907

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 2.  Non-AIDS-defining cancers among HIV-infected patients.

Authors:  James Cutrell; Roger Bedimo
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

3.  HIV Tat Impairs Neurogenesis through Functioning As a Notch Ligand and Activation of Notch Signaling Pathway.

Authors:  Yan Fan; Xiang Gao; Jinhui Chen; Ying Liu; Johnny J He
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

4.  Impacts of HIV infection and long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16.

Authors:  Korntip Amornthatree; Hutcha Sriplung; Winyou Mitarnun; Wipawee Nittayananta
Journal:  J Oral Pathol Med       Date:  2011-11-18       Impact factor: 4.253

5.  Pathway analysis for RNA-Seq data using a score-based approach.

Authors:  Yi-Hui Zhou
Journal:  Biometrics       Date:  2015-08-10       Impact factor: 2.571

6.  Flt3L and GM-CSF enhance anti-tumor effect of HPV16/18 vaccine via increasing immune response.

Authors:  Yu Liu; Haiyan Zhu; Laiming Mo; Rui Xu; Xiangyun Li; Tian Li; Liang Zhao; Yi Ren; Rongying Ou; Yunsheng Xu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

7.  Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.

Authors:  Roger J Bedimo; Kathleen A McGinnis; Melinda Dunlap; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

Review 8.  Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Roger Bedimo
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

Review 9.  Human papillomavirus-related diseases in HIV-infected individuals.

Authors:  Elizabeth A Stier; Amy S Baranoski
Journal:  Curr Opin Oncol       Date:  2008-09       Impact factor: 3.645

10.  View and review on viral oncology research.

Authors:  Valeria Bergonzini; Cristiano Salata; Arianna Calistri; Cristina Parolin; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2010-05-24       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.